Compare WTBA & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | SENS |
|---|---|---|
| Founded | 1893 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.6M | 496.0M |
| IPO Year | 2002 | 2014 |
| Metric | WTBA | SENS |
|---|---|---|
| Price | $28.93 | $9.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $24.00 | $18.38 |
| AVG Volume (30 Days) | 56.4K | ★ 735.7K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | ★ 35.21 | N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $16,389,000.00 |
| Revenue This Year | $23.80 | $74.15 |
| Revenue Next Year | $9.39 | $58.60 |
| P/E Ratio | $23.25 | ★ N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $19.03 | $0.41 |
| 52 Week High | $30.33 | $10.15 |
| Indicator | WTBA | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 65.21 |
| Support Level | $27.54 | $5.36 |
| Resistance Level | $28.80 | $9.99 |
| Average True Range (ATR) | 0.63 | 0.51 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 68.51 | 48.28 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings, and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.